Document Type

Article

Publication Date

10-31-2023

Comments

This article, first published by Frontiers Media, is the author's final published version in Frontiers in Neurology, Volume 14, 2023, Article number 1271822.

The published version is available at https://doi.org/10.3389/fneur.2023.1271822.

Copyright © 2023 Subtirelu, Teichner, Ashok, Parikh, Talasila, Matache, Alnemri, Anderson, Shahid, Mannam, Lee, Werner, Revheim and Alavi.

Abstract

Glioblastomas (GBM) are highly invasive, malignant primary brain tumors. The overall prognosis is poor, and management of GBMs remains a formidable challenge, necessitating novel therapeutic strategies such as dendritic cell vaccinations (DCVs). While many early clinical trials demonstrate an induction of an antitumoral immune response, outcomes are mixed and dependent on numerous factors that vary between trials. Optimization of DCVs is essential; the selection of GBM-specific antigens and the utilization of 18F-fludeoxyglucose Positron Emission Tomography (FDG-PET) may add significant value and ultimately improve outcomes for patients undergoing treatment for glioblastoma. This review provides an overview of the mechanism of DCV, assesses previous clinical trials, and discusses future strategies for the integration of DCV into glioblastoma treatment protocols. To conclude, the review discusses challenges associated with the use of DCVs and highlights the potential of integrating DCV with standard therapies.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English

Share

COinS